Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
  • SMC Global Securities Limited
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
Budget 2023
Budget 2023
you are here: HomeNewsBusiness

PNB Vesper gets DCGI nod to test its experimental drug on Covid-19 patients

The company has filed the clinical trial application with the DCGI for the Phase 2 clinical trials, and the study will be completed in 60 days. The study will be conducted on 40 Covid-19 positive patients at BMJ Medical College, Pune.

September 11, 2020 / 03:20 PM IST
Representative image

Representative image

PNB Vesper, a Kochi-based life sciences company, on September 11 said it has received approval from the Drugs Controller General of India (DCGI) to conduct the Phase 2b clinical trial of their propriety drug PNB-001 (GPP-Baladol) on COVID-19 patients.

The company has filed the clinical trial application with the DCGI for the Phase 2 clinical trials, and the study will be completed in 60 days. The study will be conducted on 40 Covid-19 positive patients, who are moderate patients on oxygen support, at BMJ Medical College, Pune.

The effect of PNB-001 will be compared with dexamethasone, currently the most popular medicine in Covid-19 treatment in the world.

A larger population, approximately 350 Covid-19 patients, will be enrolled across the country in six medical colleges in the phase 3 clinical trials after reviewing the phase 2 clinical trial results, the life science start-up said.